Newser reports the unapproved weight loss drug is turning up contaminated, and that vials were even found for sale in a Brooklyn bodega.
Recap by typeshit. Full story at Newser.
The actor backed Ozempic in an interview while saying exercise has no shortcut. Doctors break down whether his advice holds up.
A BusinessWorld piece on FDA worries about unapproved GLP-1 weight loss drugs, including retatrutide, which is still in trials. Few details were available.
Hecht walks through studies raising concerns that Ozempic and Wegovy may be tied to a rare optic nerve problem that can affect vision.
After his appetite disappeared on tirzepatide, Krasno talks with the Your Best Shot author about food and why scale weight can mask muscle, bone and testosterone loss.
A short social post suggesting the GLP-1 story goes beyond weight loss and the controversy around these drugs. It's light on specifics, so expect opinion rather than new data.
Michael Miller of TSCG joins The Real Deal's Deconstruct podcast to talk about how GLP-1 drugs could reshape demand for commercial property.
Loading…